top of page

Oak makes good medicines better!

We have one simple focus: To help patients in need by improving the ways in which pharmaceuticals are taken! As a patient-centric company, we understand that there are many barriers that prevent patients, especially children or those suffering from dysphagia from taking their medicines as prescribed. Oral Dissolvable Strips (ODS) address this challenge from many angles, including those faced by patients in high-need countries and low-resource settings. Funded by several contracts and grants from the National Institutes of Health (NIH) and endorsed by organizations such as the Stop TB Partnership, the TB Alliance, or Heartland National TB Center, we have demonstrated success creating ODS with industry-leading, high drug-loading capacity for antibiotics and anti-virals for the treatment of infectious diseases such as tuberculosis (TB, LTBI), PrEP, PEP, HIV/AIDS, and other infectious diseases. Our proprietary computational models for the optimization of polymer types and mixes significantly shorten development times.

TEAM

ed maliski_edited_edited.png
Zach 2019_edited_edited.png
2020 May_edited_edited.png
CLM_edited.webp
SMaliski_edited_edited.png

ED MALISKI, Ph. D., CEO and CSO. As a ‘big pharma veteran’ Ed Maliski knows the ins and outs of the pharmaceutical industry. Ed’s heart breaks when he sees statistics on worldwide childhood deaths, and he wants to change that. Ed is an accomplished research scientist with more than 30 years of experience in the development of pharmaceutical and biotechnology products at companies such as Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. 

​

​

​

​

​

​

maliski@oaktherapeutics.com

ZACHARY NICOLAY, Senior Research Scientist. Zachary is a pharmaceutical chemist with work experience in analysis via HPLC, Cell Culturing, In Vitro/Vivo Drug assays, Drug Delivery Formulation and Drug Encapsulation. He has received a BS in Nursing from Mid America Nazarene University, a BA in Chemistry from the University of Kansas, and holds an active Pharmacy Technician license with multiple years of experience. Zachary has been instrumental in pushing ODS technology at Oak Therapeutics.

​

​

​

​

nicolay@oaktherapeutics.com

GERHARD APFELTHALER, Ph. D., CBO and CAO. Having lived and worked in multiple countries, Gerhard is our global strategic thinker and the big picture mind of Oak Therapeutics. He has worked as a diplomat in Singapore and the United States, and as an educator and entrepreneur in the United States and Austria. He is a co-founder of AT Consult, CURE Pharmaceutical, and Start-Up Kids, and he mentors a number of start up companies around the world.

​

​

​​

 

​

​

apfelthaler@oaktherapeutics.com

CAMERON MCFARLANE, VP Corporate Development. Cameron brings two decades of business and manufacturing experience, entrepreneurial spirit and leadership to Oak Therapeutics. His diverse business acumen, proven track record of managing complex businesses, and providing high-level advisory has helped a diverse client list globally. Cameron prides himself on his ability to view obstacles as opportunities, to seek solutions and strategically and methodically conquering each challenge. 

​

mcfarlane@oaktherapeutics.com

SALLY MALISKI, PhD, RN, FAAN, VP

Communications. Sally is Dean Emeritus and Endowed Professor Emeritus in Oncology Nursing Research at the University of Kansas School of Nursing; Focuses on treatment-related symptom management and risk minimization for underserved people with cancer.

​​

​

​

​

​​​

​

​

​

​

​

​

smaliski@oaktherapeutics.com

ADVISORY BOARD

Armitige_Lisa_edited_edited.png
Adham Fares 2_edited.png
Kessler_edited_edited.png
michael-hageman_edited_edited.png

LISA ARMITIGE, MD, PhD: Assistant Medical Director, Heartland National TB Center at the University of Texas and Associate Professor of Internal Medicine, Pediatrics and Infectious Diseases, University of Texas.

ADHAM Fares, DDS, Section Chief, Dentistry and Oral Health, Department of Surgery-Calgary Zone, CAN, acting Division Lead of Adult Hospital Dentistry, and acting Director of the Foothills Hospital Dental Clinic with a focus on medically complex patients, and patients in cancer treatment. 

SARAH FINOCCHARIO KESSLER, PhD, MPH: Associate Professor, Department of Family Medicine,  University of Kansas Medical Center. Focuses on new maternal and pediatric HIV innovations.

MICHAEL HAGEMAN, PhD: Professor, School of Pharmacy, University of Kansas industry experience at Bristol Myers Squibb, Pfizer. Expert in physicochemical characterization and preclinical assessment of new chemical entities / small molecule therapeutics.

Lowenthal_edited.png
JRF-Web-James_Rossman_edited.png

ELIZABETH LOWENTHAL, MD, MSCE: Pediatrician with expertise in pediatric and adolescent HIV care. Staff physician at the Special Immunology Family Care Center at the Children’s Hospital of Philadelphia. Extensive experience in the treatment of HIV in Africa.

JAMES ROSSMAN: President of JRF Technologies, a leader in the development and manufacturing of edible thin films. Recognized expert on water-soluble polymers with numerous patents.

Interested in hearing more? Contact us!

  • LinkedIn
  • Twitter

31416 Agoura Rd. Ste. 105

Westlake Village, CA 91361

​

OAK THERAPEUTICS, INC.

​

2029 Becker

Lawrence, KS 66047

​

office@oaktherapeutics.com

ph +1 (913) 346-0990

bottom of page